Spravato vs IV Ketamine: How Clinicians Decide
Patients researching ketamine-based treatments often encounter two distinct options: Spravato (esketamine nasal spray) and intravenous (IV) ketamine infusions. Both involve ketamine-related compounds and both are used in clinical practice for difficult-to-treat depression. But they are not interchangeable, and the decision between them involves a set of clinical, logistical, and coverage considerations that are worth understanding before you speak with a provider.
The Core Regulatory Difference
The most important distinction between the two is regulatory status. Spravato holds FDA approval for two specific indications: treatment-resistant depression in adults, and major depressive disorder with acute suicidal ideation or behavior. That approval came in 2019 and was expanded in August 2020. Because it is FDA-approved, Spravato can be prescribed on-label, billed to insurance using established codes, and dispensed through the Spravato REMS program.
IV ketamine infusions use racemic ketamine — a mixture of the R and S enantiomers — which is FDA-approved as an anesthetic but not specifically approved for depression. When clinicians use IV ketamine for mental health conditions, they are using it off-label. That is a common and legally permissible practice in medicine, but it has implications for insurance coverage, documentation, and the structure of care.
The FDA’s Spravato prescribing information provides the official clinical basis for Spravato’s indications and administration requirements.
Differences in Setting and Administration
Spravato must be administered in a certified healthcare setting enrolled in the Spravato REMS program. Patients self-administer the nasal spray under clinician supervision and remain on-site for two hours per session. The REMS requirement exists because esketamine carries risks of sedation, dissociation, and elevated blood pressure that require observation. Clinicians bill administration using HCPCS code S0013 for the drug itself and G2082 or G2083 for the monitoring and administration service.
IV ketamine infusions are administered by a clinician through an intravenous line, typically over 40 minutes to an hour. Infusion centers often provide a quiet, comfortable environment. Because racemic ketamine is an anesthetic, infusion settings typically have anesthesia-trained staff or anesthesiologists involved. Patients also require monitoring and cannot drive afterward.
Neither option is a brief office visit. Both require dedicated clinical infrastructure and a committed treatment schedule.
Dosing and Molecular Differences
Racemic ketamine used in IV infusions contains both the R-ketamine and S-ketamine enantiomers. Spravato contains only S-ketamine (esketamine). Research suggests the two enantiomers interact with brain receptors somewhat differently. Esketamine has a higher binding affinity at the NMDA receptor compared to R-ketamine.
IV infusions allow precise, weight-based dosing and rapid titration because the medication enters the bloodstream directly. Nasal bioavailability is lower and somewhat variable depending on nasal congestion, administration technique, and individual physiology. This is one reason the dose-response picture may differ between patients using Spravato and those receiving IV infusions.
Neither formulation has been shown to be definitively superior to the other in head-to-head trials in the published literature as of 2026. Clinicians generally consider patient response, history, and practical factors rather than assuming one is better for everyone.
How Clinicians Weigh the Decision
When a patient with treatment-resistant depression presents for evaluation, a psychiatrist or clinical provider typically considers several questions:
Insurance coverage and access. Spravato, being FDA-approved for TRD (ICD-10 F32.9, F33.2) and for MDD with acute suicidal ideation, has a path to insurance reimbursement that IV ketamine generally does not. Many commercial insurers and Medicare cover Spravato under specific criteria. IV ketamine infusions are almost always paid out-of-pocket. For patients without substantial financial resources, Spravato’s insurance pathway is a meaningful practical advantage.
Speed of clinical need. When a patient is acutely suicidal and requires rapid symptom relief, IV ketamine’s direct bloodstream delivery offers predictable onset. Spravato’s August 2020 FDA approval for MDD with acute suicidal ideation also provides an approved path in this situation, though IV ketamine’s speed and titration flexibility are valued by some clinicians in acute inpatient or crisis settings.
Prior treatment history. Some patients have previously tried one approach and are considering a switch. A clinician evaluating a patient who did not respond to Spravato may consider whether IV ketamine’s different pharmacological profile offers a meaningful alternative, and vice versa.
Patient preference and practicality. Session length, travel burden, scheduling, and comfort with self-administration versus IV placement all factor into what a patient can realistically sustain over a multi-week treatment course.
What This Means for Patients
If you are exploring ketamine-based treatment options, the most useful step is a thorough evaluation with a qualified psychiatrist who can review your diagnosis, treatment history, and circumstances. Bringing documentation of your previous antidepressant trials — including medication names, doses, and duration — will help establish whether you meet criteria for treatment-resistant depression.
Ask your provider directly: which option makes sense for my situation, and why? A clinician who has experience with both modalities should be able to walk you through their reasoning.
Contact our team to learn more about evaluation options and to understand whether Spravato may be an appropriate consideration for you.
This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.
Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.